Melbourne, June 30, 2008 (ABN Newswire) - Mesoblast Limited's (ASX:MSB; USOTC:MBLTY) "Off the Shelf" adult stem cells heal bodies without rejection or ethical issues, now about 3 years from commercialisation and trading near its lows.

The following are exerpts from a featured stock report in "OzEquities":

Mesoblast

- Mesoblast Ltd is at the forefront of next generation technology using adult human stem cells, the treatment that will increasingly replace or augment current "mechanical" intervention through surgery - whether in renewing worn out or damaged joints, or rejuvenating injured hearts.

- Where Mesoblast and Angioblast's technology exceeds its competitors in its attraction is that it has patented technology to use donor stem cells - "allogeneic" cells - that can become available immediately or "off the shelf" to patients in need with none of the time delay of up to six weeks necessary for the harvesting and culture of the patient's own "autologous" stem cells. Mesoblast's allogeneic stem cells have been accepted by all patients treated so far with no trace of immune reaction or rejection. This forms the basis of a business model akin to a pharmaceutical drug, with low costs of goods and high margins.

- Mesoblast's 39.2 pct owned sister company, Angioblast in the US, has equity investment from global healthcare company, Abbott, and there are also collaborations with Johnson and Johnson companies Cordis Corporation and Biosense Webster. Other collaborations with the major pharmas seem imminent - and will transform market perception of this unique company and its technology.

- Trading at below $1, the stock has descended from around $2.50 a year and a half ago, despite the huge advances made by the company since then, and the comparatively short road remaining to commercialisation. For investors with a three year view, an investment now is likely to be handsomely repaid.

- A treatment that is safe, that works, that is comparatively inexpensive both to produce and to purchase due to its ability to be frozen for virtual "off the shelf" instant treatment, that can potentially deliver 90 pct plus profit margins to the company on a comparable basis to a pharmaceutical - a treatment that also eliminates the expenses involved in cultivating a patient's own stem cells - and that in many cases means repeat doses on a six monthly, yearly or 5 year basis - offers Mesoblast an immense opportunity.